October 2021
Pharmacy and Therapeutics Committee Meeting Update
At the September 13, 2021 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed the medication below and decided the following:
Name & Indication | Decision |
Verquvo (vericiguat): Indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics in adults with symptomatic chronic HF and ejection fraction less than 45%. | Premium and Value formularies: Preferred brand Core NH formulary: Medicare Advantage formulary: |
Wegovy (semaglutide 2.4mg injection): Indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. | Premium and Value formularies: Non-preferred brand with prior authorization and quantity limit Core NH formulary: Medicare Advantage formulary: |
Publication Information
Annmarie Dadoly,
Editor
Joseph O’Riordan,
Writer
Kristin Edmonston,
Production Coordinator